PriceTargets.com logo

Lexeo Therapeutics - LXEO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.80
  • Forecasted Upside: 256.82%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$6.67 As of 01/2/2025 06:21 PM ET
▲ +0.09 (1.37%)

This chart shows the closing price for LXEO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lexeo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LXEO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LXEO

Analyst Price Target is $23.80
▲ +256.82% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Lexeo Therapeutics in the last 3 months. The average price target is $23.80, with a high forecast of $28.00 and a low forecast of $19.00. The average price target represents a 256.82% upside from the last price of $6.67.

This chart shows the closing price for LXEO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Lexeo Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/10/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2025

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024HC WainwrightBoost TargetBuy ➝ Buy$21.00 ➝ $23.00
11/13/2024Chardan CapitalBoost TargetBuy ➝ Buy$23.00 ➝ $25.00
11/13/2024Leerink PartnersLower TargetOutperform ➝ Outperform$20.00 ➝ $19.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
10/25/2024Chardan CapitalReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
8/14/2024Chardan CapitalReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
8/13/2024HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $21.00
8/13/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$24.00 ➝ $24.00
7/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
7/15/2024Chardan CapitalReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
6/13/2024Baird R WUpgradeStrong-Buy
6/13/2024Robert W. BairdInitiated CoverageOutperform$28.00
6/6/2024HC WainwrightInitiated CoverageBuy$22.00
11/28/2023Leerink PartnrsReiterated RatingOutperform
11/28/2023JPMorgan Chase & Co.Initiated CoverageOverweight$20.00
11/28/2023Stifel NicolausInitiated CoverageBuy$20.00
11/28/2023Royal Bank of CanadaInitiated CoverageOutperform$22.00
11/28/2023Leerink PartnersInitiated CoverageOutperform$19.00
11/28/2023Chardan CapitalInitiated CoverageBuy$23.00
(Data available from 1/2/2020 forward)

News Sentiment Rating

0.93 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 11 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2025

Current Sentiment

  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Lexeo Therapeutics logo
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Read More

Today's Range

Now: $6.67
Low: $6.50
High: $6.99

50 Day Range

MA: $7.36
Low: $6.00
High: $9.97

52 Week Range

Now: $6.67
Low: $5.77
High: $22.33

Volume

174,055 shs

Average Volume

250,144 shs

Market Capitalization

$220.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Lexeo Therapeutics?

The following sell-side analysts have issued research reports on Lexeo Therapeutics in the last year: Baird R W, Chardan Capital, HC Wainwright, Leerink Partners, Robert W. Baird, and Royal Bank of Canada.
View the latest analyst ratings for LXEO.

What is the current price target for Lexeo Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Lexeo Therapeutics in the last year. Their average twelve-month price target is $23.80, suggesting a possible upside of 259.0%. Robert W. Baird has the highest price target set, predicting LXEO will reach $28.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $19.00 for Lexeo Therapeutics in the next year.
View the latest price targets for LXEO.

What is the current consensus analyst rating for Lexeo Therapeutics?

Lexeo Therapeutics currently has 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LXEO will outperform the market and that investors should add to their positions of Lexeo Therapeutics.
View the latest ratings for LXEO.

What other companies compete with Lexeo Therapeutics?

Other companies that are similar to Lexeo Therapeutics include Cogent Biosciences, Phibro Animal Health, Replimune Group, uniQure and 89bio. Learn More about companies similar to Lexeo Therapeutics.

How do I contact Lexeo Therapeutics' investor relations team?

Lexeo Therapeutics' physical mailing address is 345 Park Avenue South, 6th Floor, New York, NY 10010, United States. The company's listed phone number is 212-547-9879 and its investor relations email address is [email protected]. The official website for Lexeo Therapeutics is www.lexeotx.com. Learn More about contacing Lexeo Therapeutics investor relations.